Nanoformulation of Geranylgeranyltransferase-I Inhibitors for Cancer Therapy: Liposomal Encapsulation and pH-Dependent Delivery to Cancer Cells.
Small molecule inhibitors against protein geranylgeranyltransferase-I such as P61A6 have been shown to inhibit proliferation of a variety of human cancer cells and exhibit antitumor activity in mouse models. Development of these inhibitors could be dramatically accelerated by conferring tumor targeting and controlled release capability. As a first step towards this goal, we have encapsulated P61A6 into a new type of liposomes that open and release cargos only under low pH condition. These low pH-release type liposomes were prepared by adjusting the ratio of two types of phospholipid derivatives. Loading of geranylgeranyltransferase-I inhibitor (GGTI) generated liposomes with average diameter of 50-100 nm. GGTI release in solution was sharply dependent on pH values, only showing release at pH lower than 6. Release of cargos in a pH-dependent manner inside the cell was demonstrated by the use of a proton pump inhibitor Bafilomycin A1 that Increased lysosomal pH and inhibited the release of a dye carried in the pH-liposome. Delivery of GGTI to human pancreatic cancer cells was demonstrated by the inhibition of protein geranylgeranylation inside the cell and this effect was blocked by Bafilomycin A1. In addition, GGTI delivered by pH-liposomes induced proliferation inhibition, G1 cell cycle arrest that is associated with the expression of cell cycle regulator p21CIP1/WAF1. Proliferation inhibition was also observed with various lung cancer cell lines. Availability of nanoformulated GGTI opens up the possibility to combine with other types of inhibitors. To demonstrate this point, we combined the liposomal-GGTI with farnesyltransferase inhibitor (FTI) to inhibit K-Ras signaling in pancreatic cancer cells. Our results show that the activated K-Ras signaling in these cells can be effectively inhibited and that synergistic effect of the two drugs is observed. Our results suggest a new direction in the use of GGTI for cancer therapy.
Dept. of Microbiology, Immunology and Molecular Genetics, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA 90095, United States of America.
Jie
J
Lu
DDS Research Laboratory, NOF CORPORATION, Kawasaki, Kanagawa 210-0865, Japan.
Kohei
K
Yoshimura
Division of Applied Life Science, Graduate School of Engineering, Sojo University, Kumamoto, Japan.
Koichi
K
Goto
Dept. of Chemistry and Biochemistry, University of California Los Angeles, Los Angeles, CA 90095, United States of America.
Craig
C
Lee
DDS Research Laboratory, NOF CORPORATION, Kawasaki, Kanagawa 210-0865, Japan.
Ken
K
Hamura
Dept. of Chemistry and Biochemistry, University of California Los Angeles, Los Angeles, CA 90095, United States of America.
Ohyun
O
Kwon
Dept. of Microbiology, Immunology and Molecular Genetics, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA 90095, United States of America.
Fuyuhiko
F
Tamanoi
D019883:Alkyl and Aryl Transferases / Q000037:antagonists & inhibitors*; D059447:Cell Cycle Checkpoints / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D016503:Drug Delivery Systems; D004791:Enzyme Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D008081:Liposomes / Q000008:administration & dosage* / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy*; D010649:Phenylalanine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017368:Protein Prenylation / Q000187:drug effects; D013449:Sulfonamides / Q000008:administration & dosage* / Q000627:therapeutic use
D004791:Enzyme Inhibitors; D008081:Liposomes; C585533:P61A6 compound; D013449:Sulfonamides; D010649:Phenylalanine; D019883:Alkyl and Aryl Transferases; C083291:geranylgeranyltransferase type-I